MD Anderson and Phoenix SENOLYTIX announced a cross-licensing agreement for CaspaCIDe, used to activate cell-elimination "safety switch" technology in cell and gene therapies.
Phoenix SENOLYTIX is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging
Phoenix SENOLYTIX is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging. Its lead programs are based on its two novel gene therapy platforms, ApoptiCIDe-CE and ApoptiCIDe-RGT, which utilize proprietary enhanced cell elimination switch technology.